IS6476A - Compounds useful for the treatment or prevention of a disease occurring through alpha-2B-adrenoceptor receptors - Google Patents

Compounds useful for the treatment or prevention of a disease occurring through alpha-2B-adrenoceptor receptors

Info

Publication number
IS6476A
IS6476A IS6476A IS6476A IS6476A IS 6476 A IS6476 A IS 6476A IS 6476 A IS6476 A IS 6476A IS 6476 A IS6476 A IS 6476A IS 6476 A IS6476 A IS 6476A
Authority
IS
Iceland
Prior art keywords
alpha
prevention
treatment
compounds useful
disease occurring
Prior art date
Application number
IS6476A
Other languages
Icelandic (is)
Inventor
Wurster Siegfried
Engström Mia
Huovinen Liisa
Kalliokoski Leila
Kelanne Leila
Savola Eeva-Liisa
Original Assignee
Oy Juvantia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20000303A external-priority patent/FI20000303A0/en
Application filed by Oy Juvantia Pharma Ltd filed Critical Oy Juvantia Pharma Ltd
Publication of IS6476A publication Critical patent/IS6476A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IS6476A 2000-02-11 2002-07-19 Compounds useful for the treatment or prevention of a disease occurring through alpha-2B-adrenoceptor receptors IS6476A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18202100P 2000-02-11 2000-02-11
FI20000303A FI20000303A0 (en) 2000-02-14 2000-02-14 Compounds Useful for the Treatment or Prevention of Alpha-2B Adrenoceptor Mediated Disease
PCT/FI2001/000105 WO2001058454A1 (en) 2000-02-11 2001-02-07 Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor

Publications (1)

Publication Number Publication Date
IS6476A true IS6476A (en) 2002-07-19

Family

ID=26160944

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6476A IS6476A (en) 2000-02-11 2002-07-19 Compounds useful for the treatment or prevention of a disease occurring through alpha-2B-adrenoceptor receptors

Country Status (22)

Country Link
EP (1) EP1253926A1 (en)
JP (1) JP2003522148A (en)
KR (1) KR20020080413A (en)
AU (1) AU780802B2 (en)
BR (1) BR0108221A (en)
CA (1) CA2399421A1 (en)
CZ (1) CZ20022884A3 (en)
EA (1) EA200200846A1 (en)
EE (1) EE200200435A (en)
GE (1) GEP20043356B (en)
HR (1) HRP20020746A2 (en)
HU (1) HUP0300032A3 (en)
IL (1) IL151017A0 (en)
IS (1) IS6476A (en)
MX (1) MXPA02007454A (en)
MY (1) MY133957A (en)
NO (1) NO20023773D0 (en)
NZ (1) NZ520500A (en)
PL (1) PL357872A1 (en)
SK (1) SK11472002A3 (en)
WO (1) WO2001058454A1 (en)
YU (1) YU59102A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0401076A2 (en) * 2001-07-20 2004-09-28 Oy Juvantia Pharma Ltd. Alpha-2b-adrenoceptor antagonist compounds and their use for preparation of pharmaceutical compositions
FI116940B (en) 2001-07-20 2006-04-13 Juvantia Pharma Ltd Oy New N-pyrimidinyl para-aminobenzenesulfonamide derivatives as Alpha-2B adrenoceptor antagonists, useful for treating e.g. coronary heart disease, myocardial infarction, angina, restenosis and hypertension

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416432D0 (en) * 1984-06-28 1984-08-01 Wyeth John & Brother Ltd Benzoquinolizines
RU2086544C1 (en) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Benzenesulfonamide derivatives of pyrimidine or their salts, pharmaceutical composition for treatment of diseases associated with endothelin activity
US6150389A (en) * 1994-07-11 2000-11-21 Allergan Sales, Inc. Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents

Also Published As

Publication number Publication date
SK11472002A3 (en) 2003-02-04
AU780802B2 (en) 2005-04-21
HUP0300032A2 (en) 2003-05-28
EA200200846A1 (en) 2002-12-26
JP2003522148A (en) 2003-07-22
HRP20020746A2 (en) 2004-12-31
MXPA02007454A (en) 2004-08-23
EE200200435A (en) 2003-12-15
EP1253926A1 (en) 2002-11-06
YU59102A (en) 2005-11-28
CZ20022884A3 (en) 2003-02-12
WO2001058454A1 (en) 2001-08-16
GEP20043356B (en) 2004-04-13
MY133957A (en) 2007-11-30
KR20020080413A (en) 2002-10-23
HUP0300032A3 (en) 2006-01-30
NO20023773L (en) 2002-08-09
AU3551001A (en) 2001-08-20
NZ520500A (en) 2005-01-28
BR0108221A (en) 2003-03-05
CA2399421A1 (en) 2001-08-16
IL151017A0 (en) 2003-02-12
PL357872A1 (en) 2004-07-26
NO20023773D0 (en) 2002-08-09

Similar Documents

Publication Publication Date Title
IS7095A (en) Arylamine for the treatment of a condition related to GSK-3
MXPA03008142A (en) Benzimidazole anti-inflammatory compounds.
IS6785A (en) EP4 receptors for the treatment of arthritis
IS8586A (en) Oxabispidine compounds useful for the treatment of arrhythmias
IT1319039B1 (en) MONITORING EQUIPMENT OF THE CONDITIONS OF A DRIVER.
NO20022278D0 (en) Release mechanism for a downhole gasket
IS7150A (en) Compounds that affect glucokinase
DE60121357D1 (en) SERIALLY LINKED PRESSURE PREVENTION
AR028313A1 (en) A PROCEDURE FOR THE PRODUCTION OF A DEODORANT OR ANTITRANSPIRANT COMPOSITION
MXPA03009361A (en) Compounds useful as anti-inflammatory agents.
IS7153A (en) A process for the preparation of a 14-hydroxynormorphinone derivative
FI20001733A0 (en) The refractometer
NO20044188L (en) Controlled release dosage forms
NO20041132L (en) Pressure reducer.
DE50103586D1 (en) Foot Orthosis
AU4498201A (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment ofpain
ES1044997Y (en) DEVICE FOR THE DISPLACEMENT OF A BASKET FROM A FRYER
IT1320016B1 (en) PROCEDURE FOR THE MANUFACTURE OF SACCHEPROFONDE JOINT STRUCTURES.
EE200200257A (en) A device for transporting a flat section of a product separated from the product pan
IS6476A (en) Compounds useful for the treatment or prevention of a disease occurring through alpha-2B-adrenoceptor receptors
NO20030717D0 (en) Compounds for the treatment of addiction disorders
ZA200205835B (en) Compounds useful for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor.
FI20000433A0 (en) The pipe joint
ITFI20000178A0 (en) ECONOMISER FOR COMBUSTION DEVICES.
GB2368803B (en) Walking aid for the disabled